Unlike the other oral agents utilized in the treatment of diabetes SGLT2 inhibitors are not dependent upon the presence of endogenous insulin to be effective and because of this insulin-independent mode of action, the SGLT2 inhibitors have the potential to be effective in those type 1 diabetic patients who through resistance to the action of exogenous insulin have been unable to obtain adequate glycemic control. Here, SLC5A2 is linked to diabetes mellitus.